Abstract 1205P
Background
The probability of discovering mutation-based therapy through comprehensive genomic profiling (CGP) remains low. To enhance the effectiveness and efficiency of precision medicine, it is crucial to identify patients who are likely to benefit from CGP tests. This study aimed to identify characteristics of patients in which mutation-based treatments are discovered by CGP tests.
Methods
We retrospectively analyzed data from 60,655 patients registered in the Center for Cancer Genomics and Advanced Therapeutics (C-CAT) database, which covers 99.7% of cancer patients who have undergone CGP tests in Japan. We developed an eXtreme Gradient Boosting (XGBoost) machine learning model, and used clinical information as input to predict the likelihood of discovering mutation-based drugs through CGP tests. SHapley Additive exPlanations (SHAP) was employed to extract significant features contributing to the model prediction.
Results
The prediction model achieved an area under the receiver operating characteristic curve of 0.819 for the overall cancer population. Positive SHAP values were observed for patients with breast (mean SHAP in breast cancer patients: 1.66), lung (1.19), prostate (0.81), and colorectal (0.17) cancers, while negative SHAP values were associated with pancreatic (-2.40), brain (-1.37), and biliary tract (-0.44) cancers. Positive SHAP values were also associated with the presence of distant metastases and advanced age. Similar trends were observed in cancer type-specific prediction models. Distant metastasis was also associated with discovery of mutation-based therapy in the breast cancer-specific model, even after excluding liquid CGP data. In the adolescent and young adult (AYA) group, brain and bone tumors were associated with negative SHAP values.
Conclusions
Our analysis identified features that predict cases in which mutation-based treatments are discovered by CGP tests, both in the overall cancer population and within specific cancer types and the AYA group. Expedited CGP testing is recommended for patients who match the identified profile to facilitate early targeted therapy interventions.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
K. Watanabe, H. Kage: Financial Interests, Institutional, Research Funding: Konica Minolta. K. Oda: Financial Interests, Personal, Advisory Role: Chugai Pharma, Takeda, AstraZeneca/Merck, AstraZeneca, Konica Minolta; Financial Interests, Institutional, Research Funding: AstraZeneca/Merck, Konica Minolta. All other authors have declared no conflicts of interest.
Resources from the same session
1607P - Association of the lipid biomarker, PCPro, and clinical outcomes in the ENZAMET trial (ANZUP 1304)
Presenter: Lisa Horvath
Session: Poster session 10
1608P - Prostate cancer working group 4 (PCWG4) preliminary criteria using serial PSMA PET/CT for response evaluation: Analysis from the PRINCE trial
Presenter: Michael Hofman
Session: Poster session 10
1609P - PSMA-PET and PROMISE re-define stage and risk in patients with prostate cancer
Presenter: Wolfgang Fendler
Session: Poster session 10
1610P - Circulating tumour cell (CTC) enumeration and overall survival (OS) in men with metastatic castration-resistant prostate cancer (mCRPC) treated with xaluritamig
Presenter: Andrew Armstrong
Session: Poster session 10
1611P - Haematologic impact of [177Lu]Lu-PSMA-617 versus ARPI change in patients with metastatic castration-resistant prostate cancer in PSMAfore
Presenter: Kim Nguyen Chi
Session: Poster session 10
1612P - Impact of FANCA, ATM, CDK12 alterations on survival in metastatic castration-resistant prostate cancer (mCRPC)
Presenter: David Lorente
Session: Poster session 10
1613P - Clinically advanced prostate cancer (CAPC) featuring BRCA2 loss: A comprehensive genomic profiling (CGP) study
Presenter: Chiara Mercinelli
Session: Poster session 10
1614P - PSA responses and PSMA scan changes after immunotherapy for biochemically recurrent prostate cancer (BCR) without androgen deprivation therapy (ADT)
Presenter: Ravi Madan
Session: Poster session 10
1615P - A new prognostic model of overall survival (OS) in patients (pts) with metastatic hormone sensitive prostate cancer (mHSPC)
Presenter: Susan Halabi
Session: Poster session 10